Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNAC · 1 trial · 2 indications
Based on sampling between 0 and 12 hours
Based on sampling between 0 and 96 hours
| Arm | Type | Description |
|---|---|---|
| Furosemide/Rosuvastatin/SNAC/Semaglutide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Furosemide | DRUG | Oral administration A total of three single doses. |
| Rosuvastatin | DRUG | Oral administration. A total of three single doses. |
| SNAC | DRUG | Oral administration. A total of five single doses. |
| Semaglutide | DRUG | Oral administration. Once daily. |
Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * Male or female, aged 18-65 years (both inclusive) at the time of ...
SNAC is a small molecule developed by Novo Nordisk A/S that is being studied in diabetes. It is an absorption enhancer used in oral formulations of peptide drugs. SNAC has been investigated in a Phase 1 clinical trial in healthy subjects.
SNAC is being studied for use in diabetes as part of oral peptide drug formulations. It is designed to enhance the absorption of drugs like oral semaglutide. Its role is to improve the delivery of therapeutic peptides when taken by mouth.
SNAC is developed by Novo Nordisk A/S, a pharmaceutical company traded under the ticker NVO. Novo Nordisk is known for its work in metabolic diseases, including diabetes. SNAC is part of its efforts to develop oral peptide therapies.
SNAC is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. As a Phase 1 asset, it remains investigational and has not been approved by the FDA.
SNAC has been evaluated in a completed Phase 1 trial, NCT03010475, titled "A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects." The trial enrolled 41 healthy subjects in the United Kingdom.